Table 3. TARGETED DRUGS IN DEVELOPMENT OR APPROVED FOR LUNG CANCER.
| Drug | Target | Manufacturer |
|---|---|---|
| Erlotinib * | EGFR | Roche |
| PF-00299804/Dacomitinib | EGFR | Pfizer |
| Cetuximab/Erbitax ** | EGFR (Mab) | Bristol-Myers Squibb |
| Gelfitinib/Iressa * | EGFR | AstraZeneka |
| Afatinib/BIB2992* | EGFR, ERBB2 | Boehringer Ingelhime |
| CO-1686 | EGFR T790M | Clovis |
| Icotinib | EGFR | Zhejiang Beta Pharma Inc |
| Necitumumab/ IMC-11F8 | EGFR (Mab) | Lilly |
| Nimozutumab | EGFR (Mab) | Biocon |
| Neratinib | EGFR, ERBB2, ERBB4 | Pfizer |
| MGHA22 | ERBB2 (Mab) | Macrogenics |
| MM-121 | ERBB3 | Merrimack |
| AP2611 | ALK, EGFR, ROS | ARIAD Pharmaceutical |
| ASP3026 | ALK, ROS | Astellas Pharma |
| Crizotinib/Xalkori/PF-02341066 * | ALK, ROS | Pfizer |
| X-396 | ALK | Xcovery |
| LDK378 | ALK | Novartis |
| RO5424802/ CH5424802 | ALK | Roche, Chugai Pharmaceutical |
| GSK1363089/XL880/Foretinib | MET, VEGFR | GlaxoSmithKlein |
| Cabozantinib (XL184) ** | MET, RET | Exelixis |
| Onartuzumab/ MetMAb | MET (Mab) | Genentech |
| INC280 | MET | Novartis/Incyte |
| ARQ 197/Tivantinib | MET | ArQule and Daiichi Sankyo |
| AMG-102 | HGF (Mab) | Amgen |
| MGCD265 | MET, VEGFRs, Axl, Tie2, Ron | MethylGene |
| AMG 102/Rilotumumab | HGF (MET ligand) | AMGEN |
| Linsitinib/OSI-906 | IGF1-R | OSI Pharmaceuticals |
| Figitumumab | IGF1-R | Pfizer |
| cixutumumab | IGF1-R | Imclone |
| AMG 479 | IGF1-R (Mab) | Amgen |
| OSI-906/linsitinib | IGF1-R | OSI Pharmaceuticals |
| AXL1717/ Picropodophyllin | IGF1-R | Axelar AB |
| Vandetanib/ZD6474 | RET | AstraZeneka |
| BGJ398 | FGFR | Novartis |
| Dovitinib/TKI258 | FGFR | Novartis |
| AZD 4547 | FGFR | AstraZeneka |
| HGS1036 | FGFR | Five Prime Therapeutics |
| Tivozanib | VEGFRs | Aveo Oncology |
| Cediranib maleate/AZD2171/Recentin | VEGFR | AstraZeneca |
| BIBF 1120/ nintedanib | VEGFR, FGFR and PDGFR | Boehringer Ingelheim |
| HGS1036 | FGFR | |
| Reolysin | Activated RAS, KRAS | Oncolytics Biotech |
| PX-866 | PI3K | Oncothyreon |
| BKM120 | PI3K | Novartis |
| GDC0941 | PI3K | Genentech |
| BEZ235 | PI3K/mTOR | Novartis |
| BYL719 | PI3K/mTOR | Novartis |
| SAR245409 | PI3K/mTOR | Sanofi |
| Sirolimus/Rapamune | mTOR | Pfizer |
| CCI-779/temsirolimus | mTOR | Pfizer |
| Everolimus/RAD-001 | TOR | Novartis |
| DS-3078a | mTOR | Daiichi Sankyo |
| CC-223 | TORC1, 2 | Celgene |
| Temsirolimus | mTOR | Wyeth Pharmaceuticals |
| MK2206 | AKT | Merck |
| GSK2141795 | AKT | GlaxoSmithKlein |
| RAF265 | RAF | Novartis |
| MSC1936369B | MEK | Merck |
| RO4987655 | MEK | Hoffman-La-Roche |
| MEK162 trametinib/GSK1120212 | MEK | GlaxoSmithKlein |
| GDC-0973/XL518 | MEK | Exelixis |
| AZD6244/selumetinib | MEK | AstraZeneca |
| Visomodegib/GDC-0449 | Hedgehog | Genentech |
| Vanctitumab/OMP18R5 | FZD7 | OncoMed Pharmaceuticals Inc |
| MLN8237/alisertib | Aurora kinase | Millenium |
| PD0332991 | CDK4/6 | Pfizer |
| BAY1000394 | Pan CDK | Bayer |
| AT13387 | HSP90 | Astex Pharmaceuticals |
| AUY922 | HSP90 | Novartis |
| STA-9090 (Ganetespib) | HSP90 | Synta Pharmaceuticals |
| Retaspimycin/IPI-504 | HSP90 | Infinity |
| Panobinostat/ LBH589 | Histone deacetylases | Novartis |
| Entinostat/MS-275 | Histone deacetylases | Syndax |
| BMN-673 | PARP | BioMarin |
| Veliparib | PARP | Abbot |
| Immunomodulatory antibodies | ||
| Ipilimumab/Yervoy ** | CTLA-4, blocking antibody | Bristol-Myers Squibb |
| BMS-936558/MDX-1106/ONO-4538 | PD-1, blocking antibody | Bristol-Myers Squibb |
| MK-3475/Lambrolizumab | PD-1, blocking antibody | Merck |
| BMS-936559 | PD-L1, blocking antibody | Bristol-Myers Squibb |
| MPDL3280A/RG7446 | PD-L1, blocking antibody | Roche |
| MEDI4736 | PD-L1, blocking antibody | AstraZeneca |
*
FDA approved for NSCLC
**
FDA approved for other malignancies